Natera reported Q4 2025 revenues and earnings that surpassed its internal projections, driven by increased test volumes across its three main business segments—reproductive health, oncology, and organ transplant. Each area delivered mid‐to‐high single‐digit volume gains, contributing to overall top‐line outperformance.

The company forecasted mid-20% year-over-year revenue growth for fiscal 2026, citing expectations for sustained test‐volume expansion and pricing leverage. Management highlighted ongoing investments in lab capacity and a deepening product pipeline as key drivers of the projected growth.

Shares climbed as much as 4.3% intraday and closed up 3.7% after investors digested the beat and outlook. Natera stock has recorded 12 moves greater than 5% in the past year, trades 18.4% below its 52-week high, and is down 9.3% year-to-date.